Biotech Pioneer Submits Regulation A+ Filing With For Up To $50 Million Initial Public Offering Post author:Sam Post published:September 6, 2017 Post category:BioPharma Life Sciences Jobs … Source: BioSpace You Might Also Like Astrazeneca Gets Another Boost With FDA Approval of Severe Asthma Drug November 14, 2017 3 High-Risk Biotechs That Could Pop or Drop in 2018 February 4, 2018 Ensysce Biosciences Inc. Attending NIH Conference: Cutting Edge Science Meeting Series To End The Opioid Crisis: Development Of Safe, Effective, Non-Addictive Pain Treatments June 11, 2017
Ensysce Biosciences Inc. Attending NIH Conference: Cutting Edge Science Meeting Series To End The Opioid Crisis: Development Of Safe, Effective, Non-Addictive Pain Treatments June 11, 2017